Related Experiment Video
Updated: Jan 8, 2026
Derivation of Thymic Lymphoma T-cell Lines from Atm-/- and p53-/- Mice
Published on: April 3, 2011
Somatic Mutations of Thymic Epithelial Tumors Identified in the Prospective THYMOGENE Trial
Eleonora Pardini1, Federico Cucchiara2, Serena Barachini3
1Department of Translational Research and New Surgical and Medical Technologies, University of Pisa, Pisa, Italy.
Background:
The molecular landscape of thymic epithelial tumors has been partially elucidated. GTF2I mutation drives the pathogenesis in approximately 50% of tumors; however, the key molecular aberrations in the other cases remain unclear.
Methods:
We designed a panel including the most frequently mutated genes in thymic epithelial tumors and sequenced tumor and normal DNA from 70 patients prospectively accrued at a single institution in the Thymogene trial. Moreover, 19 neoplastic samples were dissociated to isolate tumor cells using flow cytometry.
Results:
GTF2I mutations were the most common, being present in 41% of patients. GTF2I mutations were prevalent in type A and AB thymomas, in Stage I-II tumors, and in patients without myasthenia gravis. The unique pattern of mutually exclusive and co-occurring mutations suggests a distinct pathogenesis for thymomas with and without GTF2I mutation. In 39% of patients, no mutations were found in the 77 genes evaluated. The absence of epithelial cells in some dissociated tumors highlights the challenge of identifying mutations in a subset of thymic epithelial tumors that lack the GTF2I mutation. Mutational signatures, including COSMIC 1, 19, and 25, were enriched, possibly linked to 5'-methylcytosine deamination and the effects of chemotherapy.
Conclusions:
GTF2I mutations drive the growth of a significant portion of thymic epithelial tumors, often in conjunction with other gene mutations. Somatic mutations are not commonly found in many GTF2I wild-type tumors, where the underlying genomic abnormalities remain elusive, even when using a dedicated tool for sequencing thymic epithelial tumors.
Insights
Genetic mutations in GTF2I drive many thymic epithelial tumors. However, the genetic causes for GTF2I-wildtype tumors remain largely unknown, posing a challenge for diagnosis and treatment.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- Thymic epithelial tumors (TETs) have a partially understood molecular basis.
- GTF2I mutations are implicated in approximately 50% of TET pathogenesis.
- The molecular drivers for the remaining TET cases are largely unknown.
Purpose of the Study:
- To investigate the molecular landscape of thymic epithelial tumors.
- To identify key genetic aberrations in TETs, particularly in GTF2I-wildtype cases.
Main Methods:
- Prospective sequencing of tumor and normal DNA from 70 patients in the Thymogene trial.
- Utilized a gene panel targeting frequently mutated genes in TETs.
- Employed flow cytometry for tumor cell isolation in 19 neoplastic samples.
Main Results:
- GTF2I mutations were the most frequent (41%), associated with specific thymoma types and early stages.
- Mutually exclusive and co-occurring mutation patterns suggest distinct pathogenic pathways.
- No mutations were detected in 39% of patients across 77 evaluated genes.
- Specific mutational signatures (COSMIC 1, 19, 25) were enriched, potentially linked to deamination or chemotherapy.
Conclusions:
- GTF2I mutations are a significant driver in a subset of TETs, sometimes with co-occurring mutations.
- Many GTF2I wild-type TETs lack common somatic mutations, indicating elusive genomic abnormalities.
- Identifying mutations in GTF2I-wildtype TETs remains challenging, even with specialized sequencing tools.
More Related Videos
Related Concept Videos
02:21Cancers Originate from Somatic Mutations in a Single Cell
01:27Tumor Immunotherapy
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
01:12Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...